Aytu Biopharma, Inc. AYTU
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -14.25M | -34.06M | -24.44M | -13.07M | -13.56M |
| Total Depreciation and Amortization | 3.93M | 4.27M | 4.44M | 4.85M | 5.38M |
| Total Amortization of Deferred Charges | 113.00K | 111.00K | 111.00K | 110.00K | 108.00K |
| Total Other Non-Cash Items | 7.66M | 27.50M | 23.80M | 11.98M | 12.14M |
| Change in Net Operating Assets | 5.83M | 3.85M | -4.50M | -5.23M | -6.00M |
| Cash from Operations | 3.28M | 1.68M | -595.00K | -1.37M | -1.94M |
| Capital Expenditure | -29.00K | -34.00K | -103.00K | -92.00K | -228.00K |
| Sale of Property, Plant, and Equipment | -- | 0.00 | 0.00 | 151.00K | 668.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -3.00M | -3.00M | -3.00M | -3.00M |
| Cash from Investing | -29.00K | -3.03M | -3.10M | -2.94M | -2.56M |
| Total Debt Issued | 0.00 | 2.24M | 6.92M | 12.46M | 8.53M |
| Total Debt Repaid | -4.85M | -1.86M | -1.86M | -1.86M | -1.86M |
| Issuance of Common Stock | -- | 14.84M | 14.84M | 14.84M | 14.84M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -3.05M | -5.33M | -6.58M | -8.62M | -6.07M |
| Cash from Financing | -7.90M | 9.90M | 13.33M | 16.83M | 15.44M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -4.64M | 8.54M | 9.63M | 12.52M | 10.95M |